Affiliation: Massachusetts General Hospital
- TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitroCecile L Tremblay
Massachusetts General Hospital, 65 Landsdowne St, Room 419, Cambridge, MA 02139, USA
Antimicrob Agents Chemother 49:3483-5. 2005..Synergy was observed with all drugs at the 90 and 95% inhibitory concentrations. The favorable drug interactions observed suggest that further clinical evaluation is warranted...
- Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelMartin S Hirsch
Harvard Medical School, Boston, Massachusetts, USA
Clin Infect Dis 47:266-85. 2008..As the roll out of antiretroviral therapy continues in developing countries, drug resistance monitoring for both subtype B and non-subtype B strains of HIV will become increasingly important...
- Initiating therapy: when to start, what to useMartin S Hirsch
Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA
J Infect Dis 197:S252-60. 2008..Some new antiretroviral drugs under study, particularly integrase inhibitors, may prove useful in treatment-naive patients...
- Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA PanelMartin S Hirsch
Harvard Medical School, Boston, MA, USA
Clin Infect Dis 37:113-28. 2003..Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation...
- Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionMartin S Hirsch
Massachusetts General Hospital, Harvard Medical School, Boston, USA
Clin Infect Dis 37:1119-24. 2003..Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension...
- Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitroCecile L Tremblay
Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts 02114, USA
Antimicrob Agents Chemother 46:1336-9. 2002..These findings suggest that SCH-C may be a useful anti-HIV drug in combination regimens and that a combination of chemokine coreceptor/fusion inhibitors may be useful in the treatment of multidrug-resistant viruses...
- Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infectionCecile L Tremblay
Massachusetts General Hospital and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
AIDS 17:1086-9. 2003..Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted...
- Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitroCecile L Tremblay
Massachusetts General Hospital, Infectious Diseases Unit, Harvard Medical School, Boston, Massachusetts, USA
Antimicrob Agents Chemother 47:3644-6. 2003..53 to 1.06 at 95% inhibitory concentrations. These studies suggest that a combination of T-20 and DAPD might be useful in the treatment of antiretroviral drug-experienced patients...
- Antiretroviral therapy in the clinicAthe M N Tsibris
Massachusetts General Hospital, Harvard Medical School, 65 Landsdowne St, Cambridge, MA 02139, USA
J Virol 84:5458-64. 2010....
- Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384Rajesh T Gandhi
Massachusetts General Hospital, Boston, MA, USA
J Acquir Immune Defic Syndr 42:426-34. 2006..To assess the effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy (ART)...
- Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virusRajesh T Gandhi
Infectious Diseases Unit, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Infect Dis 37:1693-8. 2003..Moreover, it suggests that, despite initially impaired viral fitness, a transmitted HIV-1 isolate with multiple drug resistance mutations can evolve to develop increased RC and significant pathogenicity...
- Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infectionRobert W Shafer
Stanford University Medical Center, Stanford, Calif, USA
N Engl J Med 349:2304-15. 2003..It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens...
- Comparison of sequential three-drug regimens as initial therapy for HIV-1 infectionGregory K Robbins
Harvard Medical School, Boston, USA
N Engl J Med 349:2293-303. 2003..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
- Monitoring HIV treatment in developing countriesSerena P Koenig
Division of Social Medicine and Health Inequalities, Brigham and Women s Hospital, 1620 Tremont Street, Boston, MA 02120, USA
BMJ 332:602-4. 2006
- Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
JAMA 292:251-65. 2004..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
- Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelScott M Hammer
Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
JAMA 300:555-70. 2008....
- Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA PanelPatrick G Yeni
Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
JAMA 288:222-35. 2002..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
- HIV drug resistance--a chink in the armorMartin S Hirsch
N Engl J Med 347:438-9. 2002
- Entecavir surpriseMartin S Hirsch
N Engl J Med 356:2641-3. 2007
- Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group studyAlison A Motsinger
Vanderbilt University School of Medicine, Nashville, Tennessee 37203, USA
Pharmacogenet Genomics 16:837-45. 2006..We examined whether long-term responses to efavirenz, and/or plasma efavirenz exposure, are better predicted by multilocus genetic interactions than by individual polymorphisms...
- Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panelScott M Hammer
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
JAMA 296:827-43. 2006..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
- Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines PanelMartin S Hirsch
Top HIV Med 11:150-4. 2003..We are happy to feature the latest edition in this issue of Topics in HIV Medicine. It is our hope that addressing these issues will help guide your treatment strategy decisions regarding resistance testing...
- TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitroCecile L Tremblay
Antivir Ther 10:967-8. 2005
- Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group StudyDavid W Haas
Vanderbilt University School of Medicine, Nashville, TN 37203, USA
J Infect Dis 192:1931-42. 2005..Nelfinavir is a substrate for P-glycoprotein, which is encoded by MDR1. The present study examined associations between genetic variants and long-term responses to treatment...
- Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith
Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
Antimicrob Agents Chemother 49:3558-61. 2005..There were no significant differences in efavirenz pharmacokinetics...
- Justice in Libya? Let scientific evidence prevailMartin S Hirsch
J Infect Dis 195:467-8. 2007
- Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapyAdriana Weinberg
University of Colorado School of Medicine, Denver, 80262, USA
J Infect Dis 193:488-93. 2006..CMV viremia did not appear to boost CMV-specific immunity. ELISPOT assays may be used to identify HIV-infected patients who might benefit from anti-CMV prophylactic interventions...
- A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus reMichael J Borucki
University of Texas Health Center, Tyler, TX, USA
Antiviral Res 64:103-11. 2004....